UnknownNot Applicable

Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

Thailand52 participantsStarted 2023-09-30

Plain-language summary

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Abnormal uterine bleeding more than 7 days after first DMPA injection * Provide inform consent with patient * Can understand thai language Exclusion Criteria: * Have contraindication to use Tranexamic acid and estrogen such as hypertension, Stroke, MI, DM, Renal disease, Liver disease, CA breast etc. * Have pathology in uterus from pelvic examination, pap smear and ultrasound * Current pelvic infection * Postpartum less than 6 months * History deep vein thrombosis * Breastfeeding

What they're measuring

Day to stop abnormal uterine bleeding between groups after receiving Tranexamic acid and estrogen

Timeframe: 1 week after intervention

Trial details

NCT IDNCT06067217

SponsorDepartment of Medical Services Ministry of Public Health of Thailand

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-08-01

Contact for this trial

Krittiporn Mahachiraphat, M.D.

0877996647 qqq_ruttew@live.com

View on ClinicalTrials.gov More Abnormal Uterine Bleeding trials